Liver Disease News and Research RSS Feed - Liver Disease News and Research

The liver is one of the largest solid organs of the body. It is located in the upper right part of the abdomen. Most of the organ lies under cover of the rib cage.
Incidence and severity emerging CVD risk factors may differ between genders

Incidence and severity emerging CVD risk factors may differ between genders

The incidence and severity of both traditional and emerging cardiovascular disease (CVD) risk factors as well as the response to treatment may differ between genders. In this narrative review, several emerging CVD risk factors (i.e. inflammatory and haemostatic markers, endothelial dysfunction, homocysteine, lipid disorders, microalbuminuria/proteinuria, coronary artery calcium score, arterial stiffness, periodontitis, inflammatory bowel syndrome, obstructive sleep apnea, impaired glucose metabolism, metabolic syndrome and non-alcoholic fatty liver disease) are discussed in the context of gender differences. [More]
Potential treatment target identified for fatty liver disease

Potential treatment target identified for fatty liver disease

Two proteins, p38 gamma and p38 delta, control the accumulation of fat in the liver, a process linked to the development of insulin resistance and diabetes, which are common outcomes of obesity. These findings are presented in an article published by researchers at the Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC). [More]
Genetic profiling ‘feasible’ for paediatric cancer patients

Genetic profiling ‘feasible’ for paediatric cancer patients

Research published in JAMA Oncology demonstrates that tumour and germline molecular profiling is feasible in paediatric cancer patients and can have actionable findings. [More]
SLU clinical psychologist helps patients battle fears, phobias

SLU clinical psychologist helps patients battle fears, phobias

Some fear is rational, keeping us appropriately cautious in the face of dangerous animals, hot stoves and contagions that could make us ill. But rational caution can turn to irrational panic about imagined terrors that are unlikely to occur or cause much actual damage if they did. [More]
UCL-led researchers find way to assess viability of induced pluripotent stem cells

UCL-led researchers find way to assess viability of induced pluripotent stem cells

A research team led by scientists from UCL have found a way to assess the viability of 'manufactured' stem cells known as induced pluripotent stem cells (iPSCs). Published today in Nature Communications, the team's discovery offers a new way to fast-track screening methods used in stem cell research. [More]
Beta- and gamma-HPVs associated with development of head and neck cancers, finds Einstein study

Beta- and gamma-HPVs associated with development of head and neck cancers, finds Einstein study

Researchers at Albert Einstein College of Medicine have found that when human papillomavirus (HPV)-16 is detected in peoples' mouths, they are 22 times more likely than those without HPV-16 to develop a type of head and neck cancer. [More]
Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

Scientists reveal why non-alcoholic steatohepatitis worsens in obese people

In results published on October 19, 2015 in the Journal of Lipid Research, a team of translational scientists at the Medical University of South Carolina report a new reason why non-alcoholic steatohepatitis (NASH) worsens in people who are obese. [More]
Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers engineer antibodies that could potently neutralize two deadliest strains of Ebola virus

Researchers at Albert Einstein College of Medicine and the U.S. Army Medical Research Institute of Infectious Diseases have engineered the first antibodies that can potently neutralize the two deadliest strains of the virus that causes Ebola hemorrhagic fever. [More]
Long-term use of opioids increases risk of new-onset depression

Long-term use of opioids increases risk of new-onset depression

Opioids may cause short-term improvement in mood, but long-term use imposes risk of new-onset depression, a Saint Louis University study shows. [More]
Scientists identify unusual regulator of body weight, metabolic syndrome

Scientists identify unusual regulator of body weight, metabolic syndrome

Scientists at the Gladstone Institutes have discovered an unusual regulator of body weight and the metabolic syndrome: a molecular mechanism more commonly associated with brain cells. Lowering levels of P75 neurotrophin receptor (NTR)--a receptor involved in neuron growth and survival--protected mice fed a high-fat diet from developing obesity, diabetes, and fatty liver disease. [More]
GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

GPR119 could be a potential treatment target for nonalcoholic fatty liver disease

New research published in the January 2016 issue of The FASEB Journal suggests that the G-protein-coupled receptor 119 (GPR119) could be a viable treatment target for nonalcoholic fatty liver disease. This receptor has already been identified as a drug target for diabetes and obesity, and this report raises hopes that compounds that target GPR119 for diabetes or obesity might also work for non-alcoholic fatty liver disease. [More]
Alcohol limits lowered to reflect current knowledge of associated health risks

Alcohol limits lowered to reflect current knowledge of associated health risks

UK guidelines for alcohol consumption have been revised to bring them in line with current research findings. The revised guidelines, published today, state that there is not a safe limit for alcohol intake and that the risks are similar for men and women. [More]

DURECT reports successful completion of DUR-928 Phase 1 study for acute use indications

DURECT Corporation today announced the successful completion of a Phase 1 clinical trial with an injectable formulation of DUR-928 intended for acute use indications. DUR-928 is an endogenous, small-molecule, new chemical entity (NCE), which may have broad applicability in metabolic diseases such as nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), and in acute organ injuries such as acute kidney injury (AKI). [More]
MUSC researchers receive $1.68 million NIH grant to study better treatment for chronic pancreatitis, diabetes

MUSC researchers receive $1.68 million NIH grant to study better treatment for chronic pancreatitis, diabetes

MUSC researchers received a $1.68 million National Institutes of Health grant to explore a better treatment for chronic pancreatitis, with the hopes that it also may shed light on a future cure for patients with type 1 diabetes. [More]
Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies. [More]
Ebola virus and bats waging molecular battle for survival

Ebola virus and bats waging molecular battle for survival

Ebola virus and bats have been waging a molecular battle for survival that may have started at least 25 million years ago, according to a study led by researchers at Albert Einstein College of Medicine, the University of Colorado-Boulder (CU-Boulder) and the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) that published online today in the journal eLife. [More]
Novel antibody improves glucose regulation and reduces fatty liver in obese mice

Novel antibody improves glucose regulation and reduces fatty liver in obese mice

A new study by researchers from Harvard T.H. Chan School of Public Health and colleagues describes the pre-clinical development of a therapeutic that could potentially be used to treat type 2 diabetes, fatty liver disease, and other metabolic diseases. [More]
Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Regulus begins RG-125(AZD4076) Phase I study for treatment of NASH in patients with type 2 diabetes/pre-diabetes

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, announced today that dosing has begun in a first-in-human Phase I clinical study of RG-125(AZD4076), by its collaboration partner AstraZeneca. [More]
Chronic alcohol use with repeated binge drinking can cause more damage to the liver

Chronic alcohol use with repeated binge drinking can cause more damage to the liver

Excessive alcohol consumption is a global public health issue. In the United States, binge drinking is the most common form - so common, in fact, that the Centers for Disease Control and Prevention reports approximately one in six adults binge drinks about four times each month. [More]
Bile acid may help treat fatty liver disease and obesity

Bile acid may help treat fatty liver disease and obesity

A bile acid that can turn off a receptor in the gut has prevented and reversed fatty liver disease in mice, according to an international team of researchers. The compound may help treat certain metabolic disorders, such as Type 2 diabetes and obesity, as well. [More]
Advertisement
Advertisement